JPRN-UMIN000013513招募中2 期
Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer - Phase 2 clinical trial of primary systemic therapy for breast cancer Nab-Paclitaxel followed by EC for HER2- breast cancer and Docetaxel/Carboplatin/Herceptin for HER2+ breast cancer
Dept of breast oncology0 个研究点目标入组 100 人开始时间: 2014年3月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are ineligible for chemotherapy
研究者
相似试验
进行中（未招募）
1 期
Phase II clinical trial of palliativ treatment of patients with advanced non-operable gastric carcinoma: FLOT regimen followed by AIO regimen and irinotecan combined with artificial nutrition and physical activity - impact on quality of life and fatigue: FLOTIRI gastric cancer trialAdvanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junctionMedDRA version: 15.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014895-23-DEniversitätsklinikum Erlangen50
已完成
2 期
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18
进行中（未招募）
不适用
trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticariaEUCTR2013-004910-16-FRCentre Hospitalier régional Universitaire de Besançon
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
尚未招募
2 期
Phase II clinical trial of multidisciplinary therapy using risk classification based on residual tumor volume and WHO grading for pediatric ependymoma patients (JCCG EPN1501)JPRN-UMIN000023803The Japan Children's Cancer Group(JCCG)40